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ABSTRACT 
Nuclear receptors (NRs) constitute a superfamily of transcription factors and play 
important roles in physiology. Transcriptional regulation by NRs can be modulated 
through interactions with various coregulators that activate or repress transcription 
through mediating receptor and chromatin modifications as well as communicating 
with the general transcription factor machinery. Coregulators also affect NR protein 
stability, which led to the discovery that the ubiquitin-proteasome system regulates 
transcriptional activity of certain NRs. However, only a few E3 ubiquitin ligases, that 
mediate the substrate specificity in the ubiquitin-proteasome system, have been 
identified as NR coregulators. The overall aim of this thesis was to identify novel 
RING-in-between-RING (RBR) E3 ubiquitin ligases that modulate NR signaling.  
 
   In the first study of this thesis, we provide evidence that the RBR ubiquitin ligase 
RNF31 acts as a novel coregulator for the NR DAX-1 in steroidogenesis. We 
demonstrate that RNF31 interacts with, and monoubiquitinates, DAX-1 and maintains 
DAX-1 stability. RNF31 is necessary for the formation of a ternary corepressor 
complex of RNF31, DAX-1 and SMRT on the DAX-1 target gene promoters CYP19 
and Steroid Acute Regulatory protein.  
 
   In the second study, we identify the RBR ubiquitin ligase RBCK1 to be a novel cell 
cycle regulator in breast cancer cells through modulating expression of the cell cycle 
regulators Cyclin B1 and Estrogen Receptor α (ERα). We demonstrate recruitment of 
RBCK1 to the breast-cancer associated ERα promoter B and find in several 
independent studies that RBCK1 mRNA correlates with ERα mRNA expression in 
breast cancer.  
 
   In the third study, we demonstrate that RBCK1 interacts with ERα and enhances ERα 
transcriptional activation of its own promoter. Further, we show occupancy of the 
RBCK1-interacting protein Protein Kinase C beta 1 (PKCβI) at the ERa promoter B. 
Consistent with this, PKCβI modulates ERα expression. A ternary complex of ERα, 
RBCK1 and PKCβI on the ERα promoter B correlates with histone modifications 
associated with a permissive chromatin environment. Taken together, the two final 
studies suggest an ERα coactivator function of RBCK1 at the ERα promoter. 
 
    In conclusion, the papers included in this thesis demonstrate that the RBR ubiquitin 
ligases RNF31 and RBCK1 are novel NR-interacting proteins that modulate NR-
dependent transcription through non-proteolytic coregulatory functions. Both the 
ligases are recruited to receptor target gene promoters and are necessary for formation 
of transcriptional complexes associated with repression and activation, respectively. 
These findings clearly support a coregulatory function of E3 ubiquitin ligases in NR 
signaling beyond degradation. 
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1 POPULAR SCIENTIFIC SUMMARY IN SWEDISH 
1.1 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Kärnreceptorer är mottagare i våra celler som reglerar viktiga fysiologiska funktioner. 
Receptorerna reglerar cellulära funktioner genom att binda till specifika regulatoriska 
regioner i vår arvsmassa och därmed bestämma om kodande delar av arvsmassan, så 
kallade gener, ska aktiveras eller inaktiveras. Detta leder till ökade eller minskade 
nivåer av proteiner i våra celler och påverkan på cellulära funktioner. Syftet med denna 
avhandling har varit att bestämma hur förmågan hos kärnreceptorer att aktivera eller 
inaktivera gener påverkas av en specifik typ av enzymer, så kallade ubiquitin ligaser. 
      
Ubiquitin ligaser är enzymer som sätter ett litet protein kallat ubiquitin på andra 
proteiner, denna process kallas ubiquitinering. Från början trodde man att 
ubiquitinering endast ledde till nedbrytning av proteinet dock har man det senaste 
decenniet påvisat att ubiquitin ligaser kan ha regulatoriska egenskaper vid aktivering av 
gener. Man har identifierat att ett fåtal av dessa ubiquitin ligaser binder till 
kärnreceptorer och påverkar deras förmåga att reglera genaktivitet. 
     
Studie I: I binjuren finns en kärnreceptor kallad DAX-1 som påverkar binjurefunktion 
genom att reglera produktionen av hormoner. DAX-1 binder till andra kärnreceptorer 
och motverkar deras aktivering av gener. Hitintills vet man inte hur DAX-1 regleras 
eller aktiveras. I denna studie identifierade vi att ubiquitin ligaset RNF31 binder till 
DAX-1 och ökar förmågan hos DAX-1 att motverka aktivering av gener viktiga för 
hormonproduktion.   
 
Studie II och III: Östrogen är ett hormon som binder till specifika kärnreceptorer, 
östrogenreceptor α och β, i våra celler. När östrogen binder till östrogenreceptor α blir 
receptorn aktiv i cellen och binder till specifika regioner i vår arvmassa vilket leder till 
ökade nivåer av proteiner som stimulerar celltillväxt. I utveckling av bröstcancer ökar 
den intracellulära mängden östrogenreceptor α och celltillväxt sker ohämmat. Ökade 
nivåer av receptorn är en stark riskfaktor för utveckling av bröstcancer och användning 
av läkemedel som motverkar bindning av östrogen till receptorn är vanlig behandling 
för bröstcancerpatienter. Dock förekommer resistans till sådan behandling, därför är det 
viktigt att öka vår förståelse för hur östrogenreceptor α kan regleras.  
                                                                                      RBR ubiquitin ligases in NR signaling 
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    I studie II identifierade vi att nivån av östrogenreceptor α i bröstcancerceller 
påverkas av ubiquitin ligaset RBCK1. När vi tog bort RBCK1 från bröstcancercellerna 
minskade nivån av receptorn och celltillväxten hämmades. Vi observerade att RBCK1 
binder till specifika regulatoriska regioner i vår arvsmassa som aktiverar genen för 
östrogenreceptor α.  
     I studie III karaktäriserade vi hur RBCK1 reglerar aktiviteten av genen för 
östrogenreceptor α i bröstcancerceller. Vi identifierade att RBCK1 tillsammans med 
östrogenreceptor α och protein kinas C β 1 (PKCβ1)  binder till arvsmassan vilket leder 
till kemiska förändringar i arvsmassan som stimulerar aktivering av genen för 
östrogenreceptor α. Genom att motverka PKCβ1  kunde vi minska den intracellulära 
nivån av receptorn.  
    Vår förhoppning är studierna i denna avhandling kan hjälpa till att identifiera nya 
tillvägagångssätt för att behandla sjukdomar som uppkommer på grund av ohämmad 
reglering av kärnreceptorerna DAX-1 och östrogenreceptor α.  
 
Nina Gustafsson Sheppard 2012 
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2 INTRODUCTION 
2.1 NUCLEAR RECEPTORS 
Nuclear receptors (NRs) constitute a superfamily of transcription factors that play a 
central role in diverse physiological functions such as metabolism, reproduction and 
development. Their importance is highlighted by the fact that NRs are common 
pharmacological targets in inflammation-related diseases and cancer. In humans, 48 
NRs have been identified. The receptors are structurally and functionally related, 
illustrated by their modular structure that includes six domains: a variable N-terminal 
domain A/B, a conserved DNA-binding domain C (DBD), a non-conserved hinge 
domain D, a C-terminal ligand binding domain E (LBD) and a variable F domain 1,2. 
The receptors can be divided into subfamilies based on their sequence homology, see 
Figure 1 2.  
 
Small molecule substances (ligands) that bind specifically to the LBDs have been 
identified for 24 of the 48 NRs, while for the remaining 24, potential ligands have not 
yet been identified and are therefore classified as orphan receptors. NR ligands show 
large diversity in their structures, even though the receptors have a conserved structure 
for the LBD. The LBD consists of 12 α-helixes, with crystal structures revealing that 
the LBD undergoes a conformational change upon binding to ligands, involving 
repositioning of helix 12 (H12), which converts the receptor into an active holo-
conformation 3,4. H12 is part of the activating function-2 (AF-2) domain and it is the 
repositioning of this helix upon ligand-binding that enables interaction with 
transcriptional coregulators and subsequently activation or repression of gene 
expression 5. Additionally, the LBD and D domain both contain nuclear localization 
signals, and the LBD and DBD dimerization regions for receptors that dimerize. 
Depending on the identity of a given NR, the receptors form monomers, homodimers 
or heterodimers prior to DNA-binding and regulating transcription. Another activation 
function, AF-1, resides in the A/B domain. AF-1 is generally thought to mediate 
ligand-independent activation of the receptors.  
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Recognition and regulation of target genes occur via hormone response elements 
(HRE) in the DNA. The DBDs of the NRs directly contact the HRE, for which the 
consensus sequence is RGGTCA and depending on the type of receptor the sequence 
can be modified, for example, inverted or extended 6.  
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  Members	  of	  the	  human	  Nuclear	  Receptor	  Superfamily	   	   	  
SUBGROUP	  1	   	   	  
Name	   Abbreviation	   	  
Thyroid	  Hormone	  Receptor	   TRα	  
TRβ	  
	  
Retinoic	  Acid	  Receptor	   RARα	  
RARβ	  
RARγ	  
	  
Peroxisome	  Proliferator-­‐Activated	  Receptor	   PPARα	  
PPARβ	  
PPARγ	  
	  
Reverse	  erbA	   Rev-­‐erbα	  
Rev-­‐erbβ	  
	  
RAR-­‐related	  orphan	  receptor	   RORα	  
RORβ	  
RORγ	  
	  
Liver	  X	  Receptor	   LXRα	  
LXRβ	  
	  
Farnesoid	  X	  receptor	   FXRα	  
FXRβ	  
	  
Vitamin	  D	  Receptor	   VDR	   	  
Pregnane	  X	  Receptor	   PXR	   	  
Constitutive	  Androstane	  Receptor	   CAR	   	  
SUBGROUP	  2	   	   	  
Name	   Abbreviation	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  Nuclear	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  Receptor	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RXRγ	  
	  
Testis	  Receptor	   TR2	  
TR4	  
	  
Tailless	   TLL	   	  
Photo-­‐rReceptor	  Specific	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  Receptor	   PNR	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  Ovalbumin	  Upstream	  Promoter-­‐Transcription	  Factor	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ErbA2-­‐realted	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SUBGROUP	  3	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  Receptor	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  Receptor	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Glucocorticoid	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SUBGROUP	  4	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NFG-­‐Induced	  Factor	  B	   NGFIB	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  Factor	  1	   NURR1	   	  
Neuron-­‐derived	  orphan	  receptor	  1	   NOR1	   	  
SUBGROUP	  5	   	   	  
Name	   Abbreviation	   	  
Steroidogenic	  Factor	  1	   SF1	   	  
Liver	  Receptor	  Homologous	  Protein	  I	   LRH1	   	  
SUBGROUP	  6	   	   	  
Name	   Abbreviation	   	  
Germ	  Cell	  Nuclear	  Factor	   GCNF	   	  
SUBGROUP	  0	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   Abbreviation	   	  
DSS-­‐AHC	  critical	   egion	  on	  the	  chromosome,	  gene	  1	   DAX1	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  Heterodimeric	  Partner	   SHP	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Figure 2. Modular structure of Nuclear Receptor domains. NLS, nuclear localization 
signal.  
 
 
 
2.2 ESTROGEN RECEPTORS 
In the 1960’s Elwood V. Jensen discovered that the action of the steroid hormone 
estrogen was mediated by a receptor 7 that we today know as Estrogen Receptor α 
(ERα). ERα was later cloned in 1985 8. ERα is widely expressed in the human body 
including the uterus, liver, kidney, heart, mammary gland, epididymis, thyroid, 
adrenal, bone, and parts of the brain 9. A second estrogen receptor, ERβ, was cloned 
in 1996 10. ERα and β belong to the NR3A subgroup of NRs and even though they are 
encoded by different genes they display a high degree of sequence similarity in the 
DBD (98%). The sequence similarity in the LBD is 59%, consistent with this they have 
different affinities for some ligands. ERα and β are coexpressed in some tissues and the 
receptors can homo- and heterodimerize. Estrogen can also mediate signaling via the 
Membrane associated G-protein coupled ER (GPR30) 11. 
 
2.3 ESTROGEN RECEPTOR ALPHA 
2.3.1 Molecular mechanisms of ERα action  
Upon binding to estrogen, ERα regulates the expression of specific target genes that 
mediate cell proliferation, differentiation and motility. The most well studied function 
of ERα is its proliferative role in breast cancer 12. ERα is a highly dynamic protein that 
                                                                                      RBR ubiquitin ligases in NR signaling 
 
 13
can shuttle between the cytoplasm and nucleus 13, thus it promotes physiological 
functions via several mechanisms both in the nucleus and cytoplasm, as well in ligand-
dependent and ligand-independent fashions 12. 
 
2.3.1.1 Ligand-dependent mechanisms 
 
In its unliganded state, ERα is part of a multiprotein complex containing heat-shock 
proteins such as Hsp9014.  The conformational change in ERα upon binding to estrogen 
15 allows the dissociation of ERα from the complex, then dimerization of the receptor16 
17, and subsequent binding to estrogen response elements (EREs) in the DNA. Finally, 
recruitment of coactivators and GTFs occur to form a stable preinitiation complex 
leading to the activation of target genes. Upon binding to estrogen, H12 closes over the 
LBD cavity enabling interaction with coactivators via the AF-2 domain. 15. The AF-1 
domain also takes part in the ligand-dependent transcriptional activation of ERα via 
recruitment of coactivators. Depending on promoter and cell type, the AF-1 and AF-2 
domains may cooperate or act independently in ligand-dependent regulation of ERα 
target gene transcription18,19.  
 
Upon estrogen stimulation, ERα can also regulate transcription at non-ERE sites via 
indirect binding to DNA involving interaction with other transcription factors such as 
Activating Protein 1(Ap1) 20, Specificity Protein 1 (Sp1) 21 or nuclear factor kB (NFkB) 
22.  
 
2.3.1.2 Ligand-independent mechanism 
ERα can also become activated in a ligand-independent manner. Such an example is 
receptor tyrosine kinase signaling, mediated by epidermal growth factor and insulin-
like growth factor, that triggers phosphorylation of ERα in the A/B domain through the 
Ras-MAPK pathway in the absence of estrogen 23-25. This phosphorylation event 
promotes interaction with co-activators and subsequently transcriptional activation 26. 
Also phosphorylation of ERα by Protein Kinase A has been described to lead to 
transcriptional activation by ERα 27. 
 
2.3.1.3 Non-genomic ERα signaling 
Recently, methylation of ERα was linked to transcriptional activation independent of 
binding to DNA by ERα. Stimulation by estrogen induces methylation in the DBD 
Nina Gustafsson Sheppard 2012 
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leading to formation of complex with PI3K, Src and focal adhesion kinase. Activating 
Akt signaling subsequently leads to initiation of transcription and cell proliferation 28. 
Thus, ERα can influence gene expression indirectly.  
 
2.3.2 Regulation of ERα activity by ligands 
2.3.2.1 Estrogen 
 
The natural ligand for ERα is the steroid hormone estrogen.  There are 3 different 
forms of estrogen; estradiol (E2), estriol (E3) and estrone (E1). E2 has the highest 
affinity for ERα and is the predominant form of estrogen in premenopausal women 
while E1 is mainly produced in postmenopausal women. E2 and E1 are produced 
mainly in the ovaries in premenopausal women, while adipose tissue is the main 
producer of these estrogens in postmenopausal women. E3 is the predominant form of 
estrogen in pregnant women where it is produced by the placenta. 29 30. 
 
2.3.2.2 Phytoestrogens  
 
In addition to endogenous estrogen, plant-derived compounds that have a similar 
structure as estrogen, so called phytoestrogens, can also bind to ERα and exert 
antagonistic and agonistic properties 31. 
 
2.3.2.3 Selective Estrogen Receptor Modulators, 
 
A major effort by pharmaceutical companies has been put into developing synthetic 
ligands that antagonize ERα action in the breast and uterus, in order to inhibit estrogen-
stimulated cancer growth, but display agonistic properties in bone and the 
cardiovascular system, in order to maintain the beneficial effect of estrogen in these 
organs32. Selective Estrogen Receptor Modulators (SERMs) are compounds that 
display tissue-selective agonist and antagonistic responses. The basis for the SERM 
concept was the observation that Tamoxifen works as an ERα antagonist in the breast 
inhibiting cell growth, but as an ERα agonist in the uterus promoting cell growth 32. 
When ERα is bound to Tamoxifen, H12 changes its position away from the LBD 
cavity, preventing coactivators from interacting with the AF-2 domain 15. Reasons 
behind distinct agonist and antagonist profiles in different tissues were originally 
believed to include the presence and ratio of different nuclear receptor coregulators 
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interacting via the AF-1 domain and the type of promoter 33,34.  Importantly, it was 
shown that binding to Tamoxifen reveals a novel binding surface in the LBD for 
coregulators, independent of AF-2, referred to as AF-T 35,36. As Tamoxifen promots 
cell growth in the uterus and resistance to Tamoxifen is a recognized clinical problem 
in treatment of breast cancer (see section 2.4.1), structurally different SERMs have 
been developed, including Raloxifene 32.  
 
27-hydroxycholesterol was recently identified as the first endogenously occurring 
SERM. Whereas 27-hydroxycholesterol inhibits ERα action in the cardiovascular 
system 37, it stimulates proliferation in breast cancer cell models 38. As levels of 27-
hydroxycholesterol are directly related to cholesterol levels, this could provide an 
important link between breast cancer and cholesterol levels.  
 
2.3.2.4 Selective Estrogen Receptor Degraders 
 
In contrast to partial antagonists such as Tamoxifen, pure antagonists without any 
agonistic effects have also been developed. This includes ICI 182,780 (Fulvestrant), 
which is a Selective Estrogen Receptor Degrader (SERD) with high affinity binding to 
ERα. Fulvestrant inhibits dimerization of ERα and induces rapid degradation of the 
receptor by the proteasome.  
 
2.4 BREAST CANCER 
Over a century ago, George Thomas Beatson published the discovery that breast cancer 
patients benefited from the removal of ovaries 39. As the ovaries produce estrogen in 
premenopausal women 30, this report was the first to suggest a link between estrogen 
and breast cancer. Breast cancer is the most common cancer in women in the western 
world, responsible for approximately 458 400 deaths in the year 2008 40. Breast cancer 
can be classified into the following subgroups based on immunhistochemical staining 
of ERα, progesterone receptor (PR) and human epidermal growth factor receptor 2 
(HER2) 41,42; 
Luminal, subtype A:    ERα and PR positive, HER‐2 negative  
Luminal, subtype B:   ERα, PR and HER‐2 positive 
Her2 overexpression:   ERα and PR negative, HER‐2 positive 
Basal‐like:     ERα, PR and HER‐2 negative 
Nina Gus
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Autoregulation is a common feature among the NR superfamily and ERα is not an 
exception 6. ERα binding sites have been reported in the proximal promoters A and B, 
and in 3 upstream enhancers 51,52. The possible combined influence of ERα binding 
sites in upstream enhancers and proximal promoter regions on ERα expression remains 
to be determined. It is however generally thought that ERα negatively regulates its own 
expression, as expression of ERα and estrogen levels are inversely correlated under 
normal physiological conditions in the breast 53. Consistent with this, recruitment of the 
corepressor Sin3A by ERα to the proximal ERα promoter upon E2 stimulation has been 
reported 52. The inverse relationship between ERα and estrogen is lost in breast cancer 
53 and antagonist treatment with Fulvestrant or Tamoxifen leads to downregulation of 
ERα mRNA 54,55. Thus, it is possible that ERα positively regulates its own expression 
in breast cancer. Moreover, high levels of ERα, such as in development of breast 
cancer, can lead to E2-independent activation of gene expression by ERα 56,57. 
 
ERα gene amplification accounts for altered ERα expression in 50% of ERα-positive 
breast cancers 58, suggesting that other processes such as regulation of ERα expression 
or protein stability become deregulated in breast cancer. ERα mRNA containing exon 
B is overexpressed in breast cancer tissue compared to normal breast tissue and shows 
high correlation with ERα protein levels in breast cancer tissue 49. In support of this, 
studies in breast cancer cell culture show increased ERα promoter B activity 59.  This 
suggests there may be breast-cancer selective regulation of ERα via promoter B. 
 
A few transcription factors have been reported to regulate ERα gene expression in 
breast cancer cells. Positive regulation is mediated by the transcription factors Estrogen 
Receptor Factor 1 (ERF1), Forkhead Box M1 (FoxM1) and the tumour suppressor p53  
via association to the proximal ERα promoters 60-62. BARX2 is a tumour suppressor 
that activates ERα  expression through association to the promoter E and F (Stevens et 
al 2004, Stevens and Meech 2006). GATA3 binds to an enhancer region between the 
ERα promoter E and F and recruits RNA polymerase II, activating ERα gene 
expression 63. The Wilms’ tumour suppressor 1 protein represses ERα expression 64. 
 
2.4.1.2 Treatment of ERα-positive breast cancer 
In ERα-positive breast cancer SERMs that display antagonistic properties on ERα 
signaling in breast, such as Tamoxifen, are standard endocrine treatment for all stages 
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of breast cancer 65. About 80% of ERα-positive and PR-positive breast cancers are 
responsive to Tamoxifen treatment, while in ERα-positive and PR-negative breast 
cancer only 40% are responsive 66,67. However, one third of women treated with 
Tamoxifen for 5 years will have recurrent disease within 15 years 32. Another 
frequently used SERM is Raloxifene however, as therapy with Raloxifene for 8 years is 
only effective in 65% of ERα-positive breast cancer, it suggests that acquired resistance 
to Raloxifene may also occur 68. An explanation for acquired resistance was long 
believed to be due to loss of ERα expression. However, as only 15-20% of endocrine 
resistant breast tumors have loss of ERα expression 69, deregulated ERα signaling or 
possibly upregulation by alternative proliferative pathways by Tamoxifen or Raloxifene 
also contributes to resistance. Of those patients with acquired Tamoxifen resistance, 10-
20% will benefit from treatment with the pure antagonist Fulvestrant. 70,71. 
 
Aromatase inhibitors (AI) are another treatment for ERα-positive breast cancer. AI 
specifically targets CYP19 (aromatase), the rate-limiting enzyme that catalyzes the last 
step in the estrogen synthesis, thus decreasing the production of estrogen. 10-20% of 
patients with acquired resistance to Tamoxifen will benefit from treatment with 
aromatase inhibitors 70,71.  
 
2.5 COREGULATORS 
The importance of interaction with coregulators for successful transcriptional activation 
by NRs was initially demonstrated in experiments with point mutations in LBD helices 
3, 5 and 12 of ERα. The mutations did not affect interaction with ligands or DNA, 
however the AF-2 activity was completely abolished, indicating that these helices form 
a surface needed for contact with additional proteins that we today know as 
coregulators 72,73. In 1995 the first nuclear receptor coregulator, steroid receptor 
coactivator-1 (SRC-1), also known as NCOA1), was cloned 74. Even though 
coregulators are widely expressed in the human body, they are believed to be expressed 
in different ratios depending on the cell type which enables tissue-specific actions by 
NRs 75. The functional importance of coregulators are emphasized by the fact that 164 
of the currently identified coregulators have been associated to some type of disease 76. 
Coregulators can also be regulated by post-transcriptional modifications, adding an 
additional layer of complexity to gene regulation by NRs 77.  
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Coregulators can broadly be dived into coactivators or corepressors depending if they 
enhance or repress transcriptional activation by the receptor. Coactivators were 
originally thought to interact with agonist or partial antagonist bound receptors with 
corepressors interacting with the un-liganded or antagonist bound receptor 5,78. 
However, studies have shown that ligand-activated ERα can repress transcription 79 by 
recruitment of corepressors 80.   
 
To date, about 240 coactivators and 40 corepressors have been identified that interact 
with NRs. Some of these interact with several receptors while some are receptor-
specific 81. Considering the large number of coregulators in relation to the number of 
NRs, it is generally thought that coregulators form and function in multiprotein 
complexes 82,83.  
 
2.5.1 Coactivators 
Mapping the domain necessary for interaction between coactivators and the AF-2 
domain in ligand-bound nuclear receptors, led to the identification of the LXXLL-motif 
(L is leucine and X is any amino acid, also called NR-box) in coactivators 84. 
Specificity regarding the interaction between NRs and coactivators is determined by the 
amino acid sequence surrounding the LXXLL-motif 85 as well as using different 
combinations of multiple LXXLL-motifs for interaction with different nuclear 
receptors 86. Coactivators that interact with NRs through the AF-1 domain have also 
been identified 87,88.  
 
Some coactivators directly affect chromatin environment, such as SWI/SNF that 
mediates ATP-dependent chromatin remodeling and CBP/p300, SRC-1, SRC-2 and 
SRC-3 that display histone acetyltransferase activity 82.  
 
2.5.2 Corepressors 
Corepressors can also interact via LXXLL-motifs with ligand-bound receptors and thus 
compete with coactivators for binding. Some corepressors contain a specific motif 
called the CoRNR-box that is an extended LXXLL-motif used to bind to the LBD of 
their interacting NRs. The most well studied corepressors are Nuclear Receptor 
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CoRepressor (NCoR) and Silencing Mediator of Retinoid and Thyroid Receptors 
(SMRT), both of which interact with NRs through their CoRNR-boxes to form large 
protein complexes containing histone deacetylase activity 89. Tamoxifen treatment has 
been suggested to promote interaction with corepressors such as SMRT that in turn 
inhibits transcription 90,91. Treatment with glucocorticoid receptor (GR) and PR 
antagonists also show recruitment of SMRT and NCoR 92. However, in the case of the 
androgen receptor (AR), agonist-bound AR interacts with NCoR and SMRT 91. Thus, 
the mechanisms by which these corepressors interact with NRs seems to differ 
depending on type of NR.   
 
2.6 DAX-1 
Dosage-sensitive sex reversal, adrenal hypoplasia congenita, critical region on the X-
chromosome, gene 1 (DAX-1) is an orphan NR, for which no ligand has been 
identified, located on the X-chromosome 93. DAX-1 belongs to the NR0B1 subgroup of 
NRs and is mainly expressed in testis and adrenals but is also expressed in other tissues 
such as breast 94 and liver 95,96.  
 
The modular structure of DAX-1 includes an LBD in its C-terminal but lacks the hinge 
domain and the classical DBD. The N-terminal contains three LXXLL-motifs through 
which DAX-1 interacts directly with the AF-2 domain in NRs and represses their 
function, acting as a NR corepressor 97-99.  NRs that DAX-1 function as a corepressor 
for includes ERα 97, PR, AR 100, peroxisome proliferator-activated receptor γ 101, 
HNFα 96, liver X receptor α 95, Nur77 102, steroidogenic factor-1 (SF-1) and liver 
receptor homolog-1 99. DAX-1 can also bind directly to DNA and RNA via the 
LXXLL-motifs 103,104. 
 
A functional DAX-1 is important for proper steroidogenesis. Deletion of DAX-1 or 
mutated DAX-1 leads to underdevelopment of the adrenal glands with hypoplasia from 
birth, and failed production of steroid hormones, whereas duplication of DAX-1 causes 
dosage-sensitive sex reversal 93,105.  
 
In the adrenal, DAX-1 is expressed in the outer cortex, which is the area responsible for 
steroid hormone production 93. DAX-1 inhibits steroidogenesis through repression of 
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transcription of steroid acute regulatory protein (StAR) and CYP19 (aromatase) 106. 
StAR is responsible for transporting cholesterol to the inner mitochondrial membrane, 
which is the first step in steroid hormone synthesis 107. Two mechanisms for how DAX-
1 exerts its corepressor function have been suggested. Firstly, DAX-1 uses its LXXLL-
motifs to compete with coactivators for binding to the AF-2 domain of NRs. In the case 
for repression of StAR, DAX-1 interacts with SF-1, which is the transcriptional 
activator for StAR, thereby repressing SF-1 induced activation of StAR 99. Secondly, 
DAX-1 represses transcription directly, through binding to the StAR promoter via its 
C-terminal transcriptional silencing domain 106 108. Interestingly, the C-terminal 
transcriptional silencing domain is deleted in all adrenal hypoplasia congenita (AHC) 
patients 109.  
 
DAX-1 interacts with other corepressors via its LBD 110,111. Importantly, mutations in 
the C-terminal of DAX-1, particularly in helix 12, result in a more cytoplasmic 
localization of DAX-1 112. Thus, loss of interaction between DAX-1 and corepressors 
due to a change in the intracellular localization may contribute to the development of 
AHC.  
 
Surprisingly, SF-1 knockout mice display a similar phenotype as patients with DAX-1 
mutations 108. This suggests that DAX-1 and SF-1 cooperate to stimulate 
steroidogenesis, which appears in contrast to the mechanism of DAX-1 inhibition of 
SF-1 function described above. Thus, the molecular mechanism of DAX-1 is complex, 
revealing a need for further investigations.  
 
2.7 UBIQUITINATION 
Regulation of protein degradation (proteolysis) is an important process in order to 
maintain cell homeostasis. Ubiquitination is a process in which ubiquitin (Ub) becomes 
covalently attached to a protein substrate. In the case of proteolysis this leads to 
recognition of the Ub modified protein by the 26S proteasome and ultimately 
degradation of the protein.  
 
Conjugation of Ub to a protein requires three different classes of enzymes that work in 
a 3-step process: 1) the Ub activating enzyme E1 activates Ub in an ATP-dependent 
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manner 2) Ub is then transferred to the Ub conjugating enzyme E2 3) the actual 
ubiquitination takes place when E2 interacts with the Ub ligase E3 that recognizes the 
protein to be ated. E3s catalyse the formation of an isopeptide bond between a lysine 
residue in the target protein and a glycine 76 in the C-terminal of Ub, thus it is the 
combination of E2 and E3 enzymes that determine the substrate specificity 113-115. In the 
human genome there exists one E1, approximately 40 E2s and several hundreds of E3s 
114,116. E3s can be divided into 2 families based on their catalytic domain; Homologous 
to E6-AP (HECT) domain and Really Interesting New Gene (RING) finger 117. The 
main difference between the two families is the way in which they transfer Ub to the 
protein substrate, i.e aminolysis. RING E3s bring the E2-Ub thioester close enough to 
the substrate in order to transfer Ub, thus the active site is present in the E2. HECT E3s 
on the other hand contain an active site and transfer Ub directly to the protein substrate. 
 
Ub can either be conjugated to one lysine in the protein substrate, called 
monoubiquitination, several Ubs can be conjugated to multiple lysine sites in the 
protein, called multiubiquitination or finally Ubs can form polyubiquitin chains. Ub 
contains seven lysine residues, all which can conjugate to the glycine 76 in other Ubs in 
order to form distinct polyubiquitin chains. Such chains can also be formed when the 
C-terminal in one Ub links to the N-terminal in another Ub, creating linear Ub-chains. 
Proteins are recognized for degradation by the proteasome if a polyubiquitin chain of at 
least four Ubs formed at lysine 48 are attached to the substrate protein 118.  
 
Ubiquitination has also been shown to regulate functions beyond degradation. For 
example, monoubiquitination of histone 2B mediates histone 3 lysine 4 methylation 
119,120 and is an integral part in transcriptional activation while monoubiquitination of 
histone 2A is a repressive mark 121. Further, monoubiquitination of RNA polymerase II 
in transcriptional initiation is well established 122. All clearly connect ubiquitination to 
transcriptional regulation.  
 
The importance of a functional Ub-proteasome system is illustrated in a number of 
diseases, for example mutations in the gene encoding the E3 E6-AP causes familial 
Angelman Syndrome 123 whereas mutations in the gene encoding the E3 Parkin leads to 
familial Parkinson’s disease 124. Interestingly, E3s have also emerged as important 
factors for the development of breast cancer 125-127.  
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2.7.1 Ubiquitination and transcriptional activation  
Several theoretical models, explaining how ubiquitination and proteasomal activity are 
linked to transcriptional activation, have been proposed 128 129. A common feature is 
that the transcriptional activator is first activated by phosphorylation and then by 
monoubiquitination, with phosphorylation believed to tag the protein for recognition by 
the E3s. The function of monoubiquitination is to stabilize the transcriptional activator 
when bound to DNA 130. Eventually the activator becomes polyubiquitinated, which 
targets the activator for degradation. The purpose of polyubiquitination in these models 
is to allow a “fresh” activator to associate to the promoter 131. It is important to know 
that mono- and polyubiquitination can occur at different lysine sites in the activator and 
by different E3s.  
 
2.7.2 Ubiquitination and transcriptional activation by nuclear receptors 
Consistent with the above mentioned models, mutation of monoubiquitination sites in 
ERα inhibits E2-induced transcriptional activation 132 and transcriptional activation by 
AR is enhanced by monoubiquitination 133. Further, polyubiqutination of E2-bound 
ERα leads to proteasomal degradation while at the same time induces recruitment of 
RNA polymerase II to some ERα target gene promoters. The question arose as to how 
degradation of a transcriptional activator could enhance transcriptional activity. It was 
then shown that ERα binds in a cyclic manner every 45 minutes to its target promoters, 
as this initiates new rounds of transcription, proteasomal degradation is necessary to 
clear the promoter so that a “new” ERα can bind and initiate transcription 77,134. Thus 
the purpose behind polyubiquitination of a transcriptional activator and subsequent 
degradation is to allow a “fresh” activator to associate to the promoter. In support of 
this, the LMP2 subunit of the proteasome interacts with the SRC coactivators, its 
recruitment to ERα target promoters is crucial for cyclic binding of ERα, RNA 
polymerase II and SRC-1 to the promoters. It was further demonstrated that 
proteasomal activity is needed for LMP2-induced activation of ERα target gene 
promoters 135. Moreover, the coactivator SRC-3 (AIB1) was shown to be required for 
degradation of ERα in an E2-dependent manner, importantly, depletion of SRC-3 
resulting in decreased promoter occupancy of ERα and RNA polymerase II. SRC-3 was 
                                                                                      RBR ubiquitin ligases in NR signaling 
 
 25
suggested to regulate degradation of ERα through phosphorylation 136. As SRC-3 also 
interacts with the proteasomal subunit SUG-1 137, it is possible that SRC-3 could recruit 
SUG-1 in order to mediate degradation of ERα as well as target ERα for degradation 
through phosphorylation. This model seems, however, to be promoter-selective as 
inhibition of proteasome activity increases ERα target gene expression if the promoter 
mainly contains EREs, but decreases target gene expression if the promoter contains 
multiple transcription factor binding sites 138,139. It is important to note that a potential 
role for monoubiquitinated ERα in the cyclic binding to target promoters has not been 
addressed in the above mentioned studies.  
 
Similar to ERα, proteasomal activity is needed for cyclic recruitment of AR to its target 
promoters 140. Transcriptional activation by PR is dependent on proteasomal activity 
141. Additionally, degradation of NR coactivators through the ubiquitin-proteasome 
pathway has been described 142, adding one more layer of regulation to fine-tune NR-
mediated transcription.  
 
Whereas E2 treatment targets ERα for proteasomal degradation 143 and deletion of H12 
inhibits E2-induced proteasomal degradation of ERα 77, treatment with Tamoxifen 
leads to accumulation of ERα protein 134,144,145. Thus, degradation of ERα could partly 
be related to its transcriptional activity. However, unliganded ERα is also targeted for 
proteasomal degradation through interaction with the E3 ligase Carboxyl Terminus of 
Hsc70-interacting Protein (CHIP) 146. This suggests that different conformations of 
ERα affect protein stability through promoting interaction with different E3s. 
 
Importantly, not all NRs seem to require turnover by the ubiquitin-proteasome system 
to drive gene expression. Such an example is the glucocorticoid receptor where activity 
is enhanced through histone methylation and RNA polymerase II recruitment upon 
inhibition of the proteasome 147,148. Further, a study by Brady et al. in 2005 showed that 
transcriptional activation is more coupled to kinetics than binding 149. Even though 
recruitment of the proteasome to certain promoters has been demonstrated, more 
studies are needed to clarify if this is a general feature in gene regulation 150. Thus, 
cyclic recruitment on the promoter for maximum gene expression might be necessary 
for some, but not all, transcriptional activators.  
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2.7.3 E3 ubiquitin ligases as nuclear receptor coregulators 
The first reports that E3s could work as NR coregulators included the HECT E3s 
RSP5/RPF1 and E6-AP. The HECT E3 RPF1 enhanced PR and GR-mediated 
transcriptional activation 151 and E6-AP enhanced transcription mediated by the ligand-
bound PR, ERα, AR, GR, thyroid hormone receptor (TR) and retinoic acid receptors 
(RAR). However, the coactivator function of E6-AP is independent of its ub ligase 
function but dependent on its ligase domain 152. E6-AP is recruited to target gene 
promoters of AR 153 and ERα 134, supporting the theory of E6-AP being a coactivator. 
Even though the ligase activity of E6-AP was dispensable for its coactivator function, 
indications for the existence of NR coactivators affecting NR protein stability was 
demonstrated in assays with mutated coactivator interaction sites in the LBD of ERα 
which inhibited E2-induced degradation of ERα 77. 
 
Both E3s belonging to the HECT and RING families have been described as NR 
coregulators. The two most well studied examples are RING E3s that have been 
associated with oncogenic properties, the Murine double minute clone 2  (Mdm2) and 
BRCA1. 
 
Mdm2 is most well known for interacting with and targeting the tumor suppressor 
p53 for degradation. Mdm2 is frequently over-expressed in cancers and a major effort 
has been put into screening for inhibitors of its binding to p53 154. Mdm2 interacts 
with several NRs including ERα 155, GR and AR 156 157. While recruitment of Mdm2 
to AR target promoters represses AR transcriptional activity 158, Mdm2 functions as 
an ERα coactivator upon E2 treatment 155. Mdm2 interacts with the LBD of ERα and in 
a complex formed together with p53, Mdm2 polyubiquitinates ERα in an E2-dependent 
manner leading to proteasomal degradation of the receptor 159. Mdm2 also targets GR 
for proteasomal degradation 160.  
 
Mutations in BRCA is responsible for approximately 40-85 % of all familial breast 
cancers 161. BRCA1 monoubiquitinates the LBD of both agonist and antagonist bound 
ERα and represses the transcriptional activation of ERα 162-164. It functions as an 
inhibitor of ERα –mediated transcription is dependent on its ligase activity 165. 
BRCA1’s function as a breast cancer suppressor protein, and the importance of its ub 
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ligase function is highlighted by the fact that all cancer-associated mutations 
occurring in the RING domain inhibit the ligase activity 166,167. These mutations result 
in failure of ubiquitination of ERα in breast cancer cells 163, thereby correlating ERα 
ubiquitination status to breast cancer. Importantly, it has been shown that mutation of 
monoubiquitination sites in ERα inhibits E2-induced transcriptional activation 132. 
Thus, it is clear that more studies are needed in order to fully understand the function of 
monoubiquitination in transcriptional activation of ERα. BRCA1 also inhibits the 
transcriptional activity of PR 168,169.  
 
2.8 RBR E3 UBIQUITIN LIGASES 
RING-In-Between-RING (RBR) E3s are a subfamily of the RING family of E3s. In 
humans they comprise a conserved family with 13 members. The RBR domain is 
defined by 3 motifs; a N-terminal RING domain (RING1), an In-between-RING 
domain (IBR) and a C-terminal RING domain (RING2). The RING2 and IBR domains 
are characteristic for the RBR family while the RING1 resembles the RING domain in 
other RING family E3s 170-172.  
 
The RBR protein Adriane has been shown to perform ubiquitination in a manner that is 
somewhat inbetween HECT and RING E3s. Like other RING family E3s, RBRs bind 
to E2 conjugating enzymes via the RING1 domain. Ub is then transferred to the RING2 
domain to form a RING2-Ub, which ubiquitinates the protein substrate via an active-
site cysteine similar to the HECT family E3s 173. In support of this, RBRs have been 
shown to interact with the E2 conjugating enzyme  UBCH7 that lacks an active site for 
ubiquitination 174. However, it is not yet clear if this mechanism for ubiquitination is 
true for all RBR members.  
 
Cellular functions modulated by members of the RBR family includes translation 175 
and NF-kB signaling 176,177 and NR signaling 178,179. Several members of the RBR 
family have been implicated in disease. For example, loss of Parkin’s ligase activity is 
associated with Parkinson’s disease 180, Dorfin degrades SOD1 which causes familial 
amyotrophic lateral sclerosis 181 and a dominant-negative mutation in ARA54 inhibits 
transcriptional activation by AR and subsequently AR-induced prostate cancer growth 
178.  
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2.8.1 RNF31 and RBCK1 
RING finger 31 (RNF31, also called FLJ10111, PAUL, ZIBRA, HOIP), belongs to the 
RBR family and was originally identified as a muscle-specific tyrosine kinase  
receptor interacting protein 182. It is overexpressed in several types of cancers, 
including breast cancer 183. The domain structure of RNF31 includes three zinc ring-
finger motifs, a ubiquitin-associated domain (UBA) and a C-terminal RBR domain. 
UBA domains can bind to both monoubiquitin and polyubiquitin chains, however 
such functions have not been fully explored for RNF31. 
 
RBCC protein interacting with PKC 1 (RBCK1, also called RNF54, XAP3, HOIL-1) 
was identified in a yeast two-hybrid screen as a Protein Kinase C (PKC) subtype η 184, 
β 185, ζ interacting protein and with the capacity to bind to DNA 186. The C-terminal 
part of the protein contains the RBR domain, while the N-terminal domain contains an 
Ubiquitin-like (Ubl) domain and a RanBP2-type zinc finger domain. Ubl domains can 
interact with the 26 proteasome. However, this has not yet been investigated for 
RBCK1. 
 
A transcriptional activation function has been mapped to the RBR-domain of RBCK1 
in GAL4 assays 187. In support of this, the splice variant RBCK2 that lacks the RBR 
domain does not have any transcriptional activation function 188. However, no 
endogenous RBCK1 target gene has yet been identified. The RBR domain may also 
contain a nuclear localization signal as RBCK1 can shuttle between the nucleus and 
cytoplasm 189, whereas RBCK2 has a cytoplasmic localization 190. Interaction between 
RBCK1 and RBCK2 leads to a cytoplasmic localization 190 of RBCK1 and inhibition of 
the transcriptional activity 188 and ubiquitin ligase activity 191.  
 
RBCK1 and RNF31 have been implicated to have a regulatory function in PKC 
signaling, however, at the same time PKC signaling seem to regulate their ubiquitin 
ligase activity 192. RBCK1 and RNF31 interact to form a linear ubiquitin chain 
assembly complex (LUBAC) which ubiquitinates activated PKCs. In turn, PKCs 
inactive the LUBAC ligase activity 192. Consistent with this, phosphorylation of 
RBCK1 by PKCβ inhibits RBCK1’s ability to autoubiquitinate itself, thereby target 
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itself for proteasomal degradation 191. RBCK1 also regulates PKCβ mediated 
hypertrophy in cardiac myocytes 185. PKCβI was recently shown to enhance AR-
mediated transcription through phosphorylation of histone H3 threonine 6 
(H3T6ph), which protects Histone H3 dimethyl lysine 4 (H3K4me2) 193. It is not yet 
clear if PKCβI play a similar role in transcriptional activation involving RBCK1. 
 
It was recently shown that another RBR E3 called SHARPIN also takes part in LUBAC 
and that LUBAC catalyzes the formation of linear ubiquitin chains on NF-kB essential 
modulator (NEMO/IKKγ). NEMO linear ubiquitination is critical for NF-kB 
activation that regulates cell survival 194-197. RBCK1 has also been implicated in 
antiviral response, interacting with and targeting interferon regulatory factor 3 for 
proteasomal degradation 198.  
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3 AIMS OF THE STUDY 
Controlled regulation of NR signaling is central to processes such as cellular 
proliferation, differentiation and metabolism. A major focus of NR research the last 
decade has centred around how NRs regulate transcription of their target genes. In this 
respect, the identification of novel NR coregulators has increased our understanding 
into the tissue-specific response of NRs and how NR signaling becomes deregulated in 
disease199. However, it has become clear that coregulators also affect NR protein 
stability, leading to the important finding that the ubiquitin-proteasome system can 
regulate transcriptional activity of NRs200. Originally E3s were thought to only target 
proteins for degradation by the proteasome. However, in the last decade this view has 
been extended and it is now clear that the consequence of interacting with an E3 is far 
more complex. Although a few NR-interacting E3s that act as coregulators have been 
described, little is known about their molecular functions beyond potential turnover of 
NRs. Therefore, the general aim of this thesis was to identify and characterize two E3s 
belonging to the RBR subclass that are important, novel modulators of NR signaling. 
 
The specific aims were: 
 
I. To identify and characterize novel coregulatory functions of RBR ubiquitin 
ligases in nuclear receptor signaling (Paper I, II, III). 
 
II. To identify and characterize a novel DAX-1 coregulator (Paper I). 
 
III. To identify and characterize novel regulators of proliferative ERα signaling in 
breast cancer cells (Paper II, III). 
 
IV. To investigate the molecular mechanism behind potential regulation of ERα 
gene expression by RBCK1 (Paper III). 
 
 
 
 
                                                                                      RBR ubiquitin ligases in NR signaling 
 
 31
4 RESULTS AND DISCUSSION 
4.1 PAPER I 
In order to identify novel DAX-1 interacting proteins, a yeast-two hybrid screen was 
performed with DAX-1 as bait. We found that RNF31, an RBR ubiquitin ligase, 
interacted with DAX-1, this interaction was further confirmed in co-
immunoprecipitation and GST-pull down assays. The DAX-1 domain responsible for 
interaction was mapped to the third LXXLL-repeat in the N-terminal domain. 
Consistent with this, small heterodimer partner (SHP), also containing this motif, was 
the only additional NR found to interact with RNF31. The RNF31 domain required for 
DAX-1 interaction was mapped to the central ubiquitin-associated (UBA) domain. 
 
RNF31 expression was found to overlap with DAX-1 expression in steroidogenic 
tissues such as the outer layer of the adrenal cortex and testis. Interestingly, RNF31 was 
expressed in cell lines that do not express DAX-1, indicating a function beyond 
regulating DAX-1 activity. The human adrenocortical cell line H295R was chosen as a 
model system to investigate the RNF31 and DAX-1 complex as this is the only human 
steroidogenic cell line known to express DAX-1. DAX-1 and RNF31 co-localized both 
in the nucleus and cytoplasm. Consistent with the presence of an RBR ubiquitin ligase 
domain in RNF31, RNF31 mediated mono-ubiquitination in the LBD of DAX-1 in an 
RBR-dependent manner. To our knowledge, this is the first post-transcriptional 
modification described for DAX-1. RNF31 overexpression and siRNA targeting 
RNF31 demonstrated that RNF31 stabilized DAX-1 protein levels, indicating a non-
proteolytic function of RNF31.  
 
In order to investigate a role for RNF31 in DAX-1 target gene expression, we measured 
promoter reporter activity and mRNA and protein expression of DAX-1 repressed 
targets upon depletion of RNF31. StAR and CYP19 promoter activity, mRNA and 
protein expression were significantly increased in siRNF31 treated cells. Further, 
chromatin immunoprecipitation (ChIP) assays revealed that the presence of RNF31 at 
the CYP19 and StAR promoters was necessary for promoter occupancy by DAX-1 and 
the corepressor SMRT. This suggests that RNF31, DAX-1 and SMRT form a 
corepressor complex in vivo on CYP19 and StAR promoters. Recruitment of the 
ternary corepressor complex was depending on the promoter occupancy of SF-1.  
Nina Gustafsson Sheppard 2012 
 
 32
 
It is possible that RNF31 has a stabilizing role in promoter occupancy by DAX-1 and 
SMRT. RNF31-dependent monoubiquitination of DAX-1 is in support of the models of 
how DNA-associated transcription factors are stabilized through monoubiquitination. It 
would be of interest to further investigate the presence of monoubiquitination of DAX-
1 on target promoters and how this modification alter DAX-1 transcriptional ability. To 
the author’s best knowledge, presence of monoubiquitinated NRs on the actual target 
promoters has not yet been determined. Monoubiquitin fusion proteins have 
successfully been used when assaying the consequence of monoubiquitination for 
protein function201. Employing DAX-1-Ubmono with mutated lysine sites for Ub-chain 
formation in Ub, and then measure global expression profiles, would provide insight 
into if this modification generally enhances corepressor function of DAX-1 or just 
regulates a subset of DAX-1 target genes. 
 
The RNF31-interacting NR SHP belongs to the same subgroup of NRs as DAX-1 and 
can heterodimerize with DAX-1 202. However, a function of SHP in the adrenal gland 
remains to be investigated. Future studies should address a potential role for 1) SHP in 
RNF31-mediated repression of steroidogenesis in the adrenal gland and 2) RNF31 in 
SHP-expressing tissues such as the liver.  
 
As DAX-1 is expressed in other tissues than the adrenal gland, such as mammary 
tissue, it would be interesting to investigate if RNF31 also modulates DAX-1 function 
in these tissues. Further, it would be interesting to compare the phenotype of a RNF31 
knock-out mouse model to the phenotype of SF-1 knock-out mice and AHC patients.  
 
In summary, we have identified that RNF31 is a novel DAX-1 coregulator necessary 
for successful transcriptional repression of SF-1 in steroidogenesis.  
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4.2 PAPER II 
The purpose of this study was to identify novel regulators of proliferative ERα 
signaling in breast cancer cells.  
 
Three initial observations lead to the hypothesis that RBCK1 could regulate the 
proliferation of ERα-positive breast cancer cells. Firstly, through a bioinformatics 
approach, we found RBCK1 to be homologous to E3 ubiquitin ligases that regulate cell 
cycle progression. Secondly, RBCK1 is known to interact with Protein Kinase C 
subtypes implicated in estrogen signaling. Finally, using the Oncomine database, we 
found RBCK1 mRNA to be elevated in breast cancer and specifically upregulated in 
ERα-positive breast cancer.  
 
We confirmed that RBCK1 is expressed in the human breast cancer cell lines MCF-7 
and T-47D. Further, cells depleted of RBCK1 had reduced cell viability due to cell 
cycle arrest. Specifically, siRBCK1 inhibited estrogen-induced S phase progression and 
induced an estrogen-independent arrest in the G2/M phase. In line with the effect of 
estrogen on cell cycle progression being largely mediated by ERα, both ERα mRNA 
and protein levels were significantly decreased in RBCK1 depleted cells. Further, 
mRNA levels of ERα target genes Cyclin D1 and c-myc, important for progression 
from the G1 to S phase, were decreased upon RBCK1 depletion. Thus, RBCK1 
depletion impairs proliferative ERα signaling in breast cancer.  
 
The estrogen-independent cell cycle arrest upon RBCK1 depletion was correlated with 
downregulation of Cyclin B1. We hypothesized that RBCK1 might support 
transcription of Cyclin B1 through recruitment to the Cyclin B1 promoter region as the 
mRNA expression of Cyclin B1 was down-regulated by RBCK1. We could however 
not observe any recruitment of RBCK1 to the proximal Cyclin B1 promoter. This may 
be due to that RBCK1 regulates Cyclin B1 expression via unknown promoters or distal 
enhancer elements. As no response element for RBCK1 is known we were unable to 
scan Cyclin B potential regulatory regions for potentially regulatory regions using a 
bioinformatic approach.  Downregulation of Cyclin B1 could also be a secondary effect 
of RBCK1 down regulation. RBCK1 might affect signaling cascade(s) including  
transcriptional regulator(s) that regulate Cyclin B1. Overall, this highlighted one of the 
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problems with using siRNA approaches; that it is difficult to distinguish between 
primary/direct and secondary/indirect effects.  
 
As ERα mRNA levels were decreased upon RBCK1 depletion, we next determined if 
RBCK1 might have a function in regulating ERα gene transcription. Indeed, RBCK1 
was recruited to promoter B, stimulating expression from both RBCK1 promoters A 
and B. This is not surprising, since the distance between the ERα promoters A and B is 
small. To our knowledge this is the first report of an endogenous RBCK1-target gene. 
 
A positive correlation between RBCK1 and ERα expression was demonstrated in a 
small set of clinical breast cancer samples. We were able to confirm this correlation in 
larger data set from publically available clinical breast cancer microarray data using  a 
Pearson correlation test. It is important to note that the R square value was 
approximately 0.3 in all datasets meaning that RBCK1 can be held responsible for 30% 
of the ERα expression in breast cancer. Thus, it is likely that several mechanisms 
contribute to the increased levels of ERα in breast cancer. This is expected as several 
transcription factors have been described to regulate the ERα expression, as discussed 
in the section 2.4.1.1.  
 
In conclusion, we found that RBCK1 promotes cell cycle progression from both the G1 
to S phase, via promoting ERα expression and thereby ERα signaling, as well as the 
G2/M phase, possibly by modulation of Cyclin B1 expression. 
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4.3 PAPER III 
Modulation of ERα signaling by other nuclear receptors, ligands, coregulators, post-
transcriptional modifications and cell signaling has been well described 81. However, 
studies investigating regulation of ERα gene expression are limited. The aim of paper 
III was to investigate the molecular mechanism by which RBCK1 regulates ERα 
expression in breast cancer cells. 
 
From the results in paper II, we hypothesized that RBCK1 works as a transcriptional 
activator of ERα promoters A and B in breast cancer cells. We confirm here in this 
study using an ERα promoter A-B reporter construct, as well as measuring an increase 
in endogenous ERα mRNA and protein levels upon RBCK1 overexpression in MCF-7 
breast cancer cells, that RBCK1 can upregulate ERα expression.  
 
Through sequential ChIP we observed that RBCK1 and ERα co-occupy a previously 
confirmed ER binding region in the ERα promoter B. ERα has also been shown to 
associate with upstream enhancers in the ERα promoter. Importantly, we could not 
detect any recruitment of RBCK1 to these enhancers. We demonstrated that interaction 
between endogenous RBCK1 and ERα and ERα recruitment to the promoter was 
necessary for RBCK1 association to the promoter. On the contrary, RBCK1 
recruitment was not necessary for association of ERα to the ERα promoter B. 
Overexpression of RBCK1 together with ERα enhanced ERα promoter reporter activity 
approximately 10-fold compared to transfection with RBCK1 or ERα alone. Altogether 
suggesting an ERα coactivator function of RBCK1. Alternatively confirmed ERα 
corepressors such as Sin3A 52 are recruited by ERα to the promoter in the absence of 
RBCK1, resulting in repression of ERα gene expression.  
 
We found that RBCK1-mediated transcriptional activation of the ERα promoter was 
dependent on the RING2 domain. This is consistent with a previous study showing that 
the rat homologue of RBCK1 can activate transcription in GAL4 assays via its C-
terminal RBR domain 187.  
 
In support of the model suggested for RBR-mediated ubiquitination, where Ub is 
transferred from RING1 to RING2 leaving the IBR domain available for interaction 
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with the protein substrate, RBCK1 interacted with ERα via the IBR domain. As 
deletion of RING2 severely decreased the transcriptional activation by RBCK1, it is 
possible that ubiquitination mediated by RBCK1 is an important function in its 
transcriptional activation. Recent publication makes it possible to predict active sites 
necessary for Ub ligase acitvity in RBCK1 173. Future studies should include point 
mutations of such sites in order to determine if RBCK1 coactivator and Ub ligase 
activity colocalizes.  
 
As the combination of E2 conjugating enzymes and E3s mediate substrate specificity it 
would be of interest to identify the potential E2 interacting with RBCK1. Two E2s have 
been found to interact with RBR ubiquitin ligases, UBCH7 and 8203. Interestingly, 
UBCH7 is recruited to ERα target promoters204. Thus, it is possible that 1) UBCH7 
interacts with RBCK1 and 2) UBCH7 is part of the RBCK1-ERα complex on the ERα 
promoter B.    
 
Interestingly, the RBCK1-interacting protein Protein Kinase C beta 1 (PKCβ1) was 
recently implicated in regulation of AR target gene activation by phosphorylation of 
histone 3 threonine 6 (H3T6ph), that in turn protects dimethylation of lysine 4 
(H3K4me2) 193. This lead to our hypothesis that RBCK1 might support ERα 
transcriptional activation through interaction with PKCβ1, that in turn modifies H3. 
Indeed RBCK1 and PKCβ1 co-occupied the ERα promoter B. Moreover, siRBCK1 
treatment resulted in reduced promoter recruitment of PKCβ1 as well as reduced levels 
of H3T6ph and H3K4me2. As H3 lysine 4 methylation can be mediated by Histone 2B 
ubiquitination it would be interesting to investigate if RBCK1, considering its Ub ligase 
domain, can modulate this modification.  
 
Even though RBCK1 promoter occupancy was associated with a permissive chromatin 
environment it would be interesting to determine status of markers for transcriptional 
initiation such TFIID and B or phosphorylation of the C-terminal domain (CTD) of 
RNA polymerase II upon depletion of RBCK1 promoter occupancy in order to more 
specifically determine if RBCK1 is important for recruitment of GTFs to the ERα 
promoter.  
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Consistent with the transcriptional function of PKCβ1 being dependent on its kinase 
function193, we observed that ERα mRNA expression was decreased upon inhibition of 
the kinase activity. Subsequently, ERα protein levels and target gene expression of 
Cyclin D1 and c-myc were also decreased. To directly relate this decrease in ERα 
expression to PKCβ1-dependent phosphorylation of H3, we have identified that 
inhibition of the kinase activity leads to decreased H3T6 phosphorylation in the ERα 
promoter B (Gustafsson Sheppard unpublished data). PKCβ1 has previously been 
shown to affect Cyclin D1 expression by an unknown mechanism205. As Cyclin D1 is 
an ERα target gene, it is possible that the effect of PKCβ1 on ERα expression, reported 
here is to mediate the previously described observation that PKCβ1 modulates Cyclin 
D1. 
 
We could not find that the presence of E2 affected RBCK1- ERα interactions or 
transcriptional regulation of the ERα promoter. In support of a possible ligand-
independent function of the ERα-RBCK1 complex, we have determined that 1) 
Tamoxifen does not influence ERα-RBCK1 complex and 2) the non-ligand dependent 
AF-1 domain of ERα is critical for interaction with RBCK1. (Gustafsson Sheppard 
unpublished data). More experiments are needed to fully evaluate the possible 
influence by pure ERα antagonists on the RBCK1- ERα complex and function in breast 
cancer cells. 
 
In order to investigate if RBCKI and PKCβ1 are recruited to a subset of ERα target 
gene promoters or are more general coregulators for ERα, RBCK1- PKCβ1 recruitment 
was assayed at randomly selected ERα binding regions. Recruitment was confirmed at 
all selected binding regions (Gustafsson Sheppard unpublished data). Conversely, we 
could not find any recruitment of RBCK1- PKCβ1 to ERα binding sites in enhancers 
upstream the ERα gene. Since only 5% of ERα binding sites are located within 5kb 
from the transcriptional start site 206, it could be that RBCK1- PKCβ1 are recruited to a 
subset of ERα binding sites, possibly the ones located in promoter regions. Importantly, 
the AF-1 domain of ERα is needed for interaction with RBCK1 (Gustafsson Sheppard 
unpublished data).  Whether RBCK1 and PKCβ1 may be recruited to a subset of ERα 
target gene promoters possibly regulated through AF-1 activity should be focus of 
future studies. 
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Taken together, our data suggests a novel ERα coactivator function of RBCK1 in which 
RBCK1 supports transcriptional activation through enabling PKCβ1 promoter 
occupancy and subsequently PKCβ1-dependent histone modifications. Thus, a complex 
of ERα/RBCK1/PKCβ1 on the ERα promoter B would drive ERα gene expression, 
thereby promoting proliferative ERα signaling in breast cancer cells. This mechanism is 
distinct from the described mechanism by which proteolysis promotes the 
transcriptional activation function of ERα.  
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5 CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
The general aim of this thesis was to identify and characterize two E3 Ub ligaess, 
RNF31 and RBCK1, that belong to the RBR subclass that modulate NR signaling. 
Originally E3s were thought to only target proteins for degradation by the proteasome. 
However, in the last decade this view has been extended and it is now clear that the 
consequence of interacting with a E3 is far more complex, of great interest is the 
involvement of the Ub-proteasome system in transcriptional activation200. However, 
only a few NR-interacting E3s that are able to act as coregulators have been described, 
with little known regarding their molecular functions beyond the potential turnover of 
NRs 207. Our studies presented in this thesis investigate the mechanisms behind RNF31 
and RBCK1’s ability to modulate transcription through coregulatory functions. As both 
E3s are recruited to NR target gene promoters and are necessary for the formation of 
transcriptional complexes associated with repression (Paper I) or activation (Paper III), 
our novel findings clearly strengthen a coregulatory, non-proteolytic function for E3s in 
NR signaling.  
 
A major finding in this thesis is that RBCK1 supports proliferation of ERα-positive 
breast cancer cells via transcriptional regulation of ERα (Paper II, III). Considering the 
important role of ERα signaling in development and progression of a majority of breast 
cancers, it is somewhat surprising that the regulation of ERα gene expression has not 
been more characterized. Since cell-type specific promoter usage for ERα expression 
occurs47,48, identification and characterization of promoter specific transcription factors 
may aid in development of novel cell-type specific therapies manipulating ERα 
signaling in breast cancers. Furthermore, increased levels of ERα, independent of the 
presence of estrogen, result in development of ductal carcinoma in mice 208 and 
increased intracellular levels of ERα results in ligand-independent activation of the 
receptor 56,57. Additionally, ERα can become activated by growth factors 27. Thus, the 
intracellular level of ERα might be an important factor in breast cancer development as 
well as resistance to treatment. Therefore, targeting ERα in a way that eliminates 
receptor expression in breast cancer is of high interest. Targeting promoter-specific 
regulators of ERα gene expression, such as RBCK1 and potentially PKCβ1, might 
provide a novel approach, in addition to SERDs, to down-regulate the receptor in breast 
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cancer. Particularly as usage of the ERα promoter B, that according to our studies are 
regulated by RBCK1 and PKCβ1, seems to be specific for breast cancer 59. However, 
as ERα mRNA B and A are expressed in both mammary tissue and ovaries48, further 
studies investigating potential functions of RBCK1 and PKCβ1 in regulation of ERα 
expression in the ovaries are needed.  
 
Several issues have to be addressed in order to evaluate the potential of RBCK1 as a 
therapeutic target in breast cancer. Importantly, more studies are needed to fully dissect 
the specificity in RBCK1-mediated regulation of ERα in molecular, cellular and mice 
models. For example, RBCK1 have has functions beyond ERα. Thus, RBCK1 
expression and function in other tissues has to be determined in order to avoid 
unwanted effects when targeting the protein. Further, a suitable assay has to be 
developed in order to measure RBCK1 activity or function in order to perform a high-
throughput screen for novel compounds exhibiting RBCK1 inhibitory properties. The 
last 5 years, small molecules disrupting protein-protein interactions have developed as 
successful therapeutic agents 209. Thus, identifying molecules that disrupt RBCK1- ERα 
interactions would provide a strategy to inhibit RBCK1-mediated upregulation of the 
ERα promoter in breast cancer. Sensitive measurement of RBCK1 and ERα 
interactions in the presence of various compounds could be performed in a protein-
fragment complementation (PCA) assay210 with RBCK1 and ERα fused to 
complementary parts of a fluorescent protein. Lastly, investigating a functional role for 
RBCK1 by employing hits from high-throughput screenings in a mouse model of breast 
cancer such as MMTV-PyMT 211 will provide valuable information into modulation of 
breast cancerogenesis by RBCK1.  
 
Interestingly, drugs targeting PKCβI and PKCβII such as Ruboxistaurin are under 
current clinical trial for the treatment of diabetic peripheral retinopathy 212 indicating 
that PKCβ1 is a potential drug target. Whether PKCβ1 expression or kinase activity 
correlates with ERα expression in samples from breast cancer patients awaits further 
clarification. 
 
Our results show that RBCK1 and ERα mRNA expression positively correlates in 
clinical breast cancer samples. Further investigation into the expression of RBCK1 and 
PKCβ1 in 1) different stages of breast cancer, 2) short- and long-term breast cancer 
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survival, 3) response to endocrine treatment, will provide insight into a possible 
prognostic value of assessing RBCK1 or PKCβ1 expression in breast cancer.  
 
Future studies should investigate if RBCKI and RNF31 display gene promoter specific 
recruitment and if they are general coregulators for their interacting NRs. As RNF31 
and RBCK1 interact, forming the Ub ligase complex LUBAC195, it is possible that 
RNF31 and RBCK1 modulate eachothers functions as transcriptional coregulators in 
steroidogenesis and breast cancer proliferation. Future studies addressing these issues 
should also include SHARPIN, another RBR ligase, recently reported to be part of 
LUBAC. 
 
The studies presented in this thesis are focused on further elucidating the coregulatory 
functions of E3s in NR signaling. However, we have only begun to characterize 
RNF31’s role in modulating steroidogenesis and RBCK1’s ability to drive ERα-
positive breast cancer cell proliferation. Many aspects in characterizing these functions 
remain unexplored and so many exciting studies await in order to fully understand their 
mechanisms of action.  
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